NCT05723471 Impact of a Collaborative Program of Physical Activity of Newly-diagnosed Cancer Patients
| NCT ID | NCT05723471 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Toulouse |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 350 participants |
| Start Date | 2024-08-30 |
| Primary Completion | 2028-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 350 participants in total. It began in 2024-08-30 with a primary completion date of 2028-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
During the last twenty years, the cancer overall incidence has been increasing in europe and developed countries, while diagnostic and therapeutic progress have contributes to a reduction in mortality. Currently, almost 4 million people are treated or followed for cancer in France. The physical, psychological and social after-effects are significant. Adaptated physical activity plays an important role in the rehabilitation process. Overall, meta-analyses carried-out with most frequent cancers demonstrate that physical activity practiced would allow an improvement in quality of life, tolerance to anticancer treatments and survival.
Eligibility Criteria
Inclusion Criteria: * newly-diagnosed cancer patient * able to start a program of physical activity within the first year follow diagnosis * performance status between 0 to 2 Exclusion Criteria: * uncontrolled cardiovascular disease * peripheral neuropathy grade 3-4 with risk of falling * bone metastasis with risk of bone fracture * platelets \<100X109/L * hemoglobin \<8g/dL * patient under legal protection
Contact & Investigator
Stéphanie MOTTON, MD
PRINCIPAL INVESTIGATOR
University Hospital, Toulouse
Frequently Asked Questions
Who can join the NCT05723471 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05723471 currently recruiting?
Yes, NCT05723471 is actively recruiting participants. Contact the research team at bogdanovitch.l@chu-toulouse.fr for enrollment information.
Where is the NCT05723471 trial being conducted?
This trial is being conducted at Nancy, France, Toulouse, France.
Who is sponsoring the NCT05723471 clinical trial?
NCT05723471 is sponsored by University Hospital, Toulouse. The principal investigator is Stéphanie MOTTON, MD at University Hospital, Toulouse. The trial plans to enroll 350 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.